Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

Sponsor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Study ID
NCT07156253
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors

Key Dates

Start date
Aug 26, 2025
Status verified
Aug 2025
Primary completion
Aug 25, 2028
Completion
Feb 25, 2029

Study Design

Enrollment
110 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SYN818 combination with Olaparib

Primary Outcome Measure

Maximum tolerated dose (MTD) [ Time Frame: Up to 3 years ]

Central Contacts

Related Studies